204 related articles for article (PubMed ID: 25546409)
1. Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes.
Blighe K; Kenny L; Patel N; Guttery DS; Page K; Gronau JH; Golshani C; Stebbing J; Coombes RC; Shaw JA
PLoS One; 2014; 9(12):e115346. PubMed ID: 25546409
[TBL] [Abstract][Full Text] [Related]
2. Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer.
Mitrović O; Čokić V; Đikić D; Budeč M; Vignjević S; Subotički T; Gulan M; Radović S; Furtula S
Target Oncol; 2014 Dec; 9(4):367-79. PubMed ID: 24272208
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.
Cardoso F; Di Leo A; Larsimont D; Gancberg D; Rouas G; Dolci S; Ferreira F; Paesmans M; Piccart M
Ann Oncol; 2001 May; 12(5):615-20. PubMed ID: 11432618
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.
Won HS; Lee KE; Sung SH; Choi MY; Jo JY; Nam EM; Mun YC; Seong CM; Lee SN
Tumori; 2014; 100(1):80-6. PubMed ID: 24675496
[TBL] [Abstract][Full Text] [Related]
5. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization.
Murthy SK; Magliocco AM; Demetrick DJ
Arch Pathol Lab Med; 2005 Jan; 129(1):39-46. PubMed ID: 15628907
[TBL] [Abstract][Full Text] [Related]
6. Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours.
Chen B; Zhang G; Lai J; Xiao W; Li X; Li C; Mok H; Li K; Wang Y; Cao L; Jia M; Ren C; Wen L; Wei G; Lin J; Li Y; Zhang Y; Chen X; Wu X; Zhang H; Li M; Liu J; Balch CM; Liao N
EBioMedicine; 2021 Sep; 71():103542. PubMed ID: 34454403
[TBL] [Abstract][Full Text] [Related]
7. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
Arriola E; Marchio C; Tan DS; Drury SC; Lambros MB; Natrajan R; Rodriguez-Pinilla SM; Mackay A; Tamber N; Fenwick K; Jones C; Dowsett M; Ashworth A; Reis-Filho JS
Lab Invest; 2008 May; 88(5):491-503. PubMed ID: 18332872
[TBL] [Abstract][Full Text] [Related]
8. Case-only analyses of the associations between polymorphisms in the metastasis-modifying genes BRMS1 and SIPA1 and breast tumor characteristics, lymph node metastasis, and survival.
Roberts MR; Hong CC; Edge SB; Yao S; Bshara W; Higgins MJ; Freudenheim JL; Ambrosone CB
Breast Cancer Res Treat; 2013 Jun; 139(3):873-85. PubMed ID: 23771732
[TBL] [Abstract][Full Text] [Related]
9. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Bramwell VH; Andrulis IL; Pritchard KI
J Natl Cancer Inst; 2009 May; 101(9):644-50. PubMed ID: 19401546
[TBL] [Abstract][Full Text] [Related]
11. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
Jensen JD; Knoop A; Ewertz M; Laenkholm AV
Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-Related DNA Repair/Cell-Cycle Genes Independently Associated With Relapse After Radiation Therapy for Early Breast Cancer.
Gee HE; Buffa FM; Harris AL; Toohey JM; Carroll SL; Cooper CL; Beith J; McNeil C; Carmalt H; Mak C; Warrier S; Holliday A; Selinger C; Beckers R; Kennedy C; Graham P; Swarbrick A; Millar EK; O'Toole SA; Molloy T
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1104-14. PubMed ID: 26581147
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
Fountzilas G; Christodoulou C; Bobos M; Kotoula V; Eleftheraki AG; Xanthakis I; Batistatou A; Pentheroudakis G; Xiros N; Papaspirou I; Koumarianou A; Papakostas P; Bafaloukos D; Skarlos DV; Kalogeras KT
J Transl Med; 2012 Oct; 10():212. PubMed ID: 23092535
[TBL] [Abstract][Full Text] [Related]
14. Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.
Kotoula V; Bobos M; Alexopoulou Z; Papadimitriou C; Papadopoulou K; Charalambous E; Tsolaki E; Xepapadakis G; Nicolaou I; Papaspirou I; Aravantinos G; Christodoulou C; Efstratiou I; Gogas H; Fountzilas G
PLoS One; 2014; 9(8):e103707. PubMed ID: 25098819
[TBL] [Abstract][Full Text] [Related]
15. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
[TBL] [Abstract][Full Text] [Related]
17. A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.
Szekely B; Iwamoto T; Szasz AM; Qi Y; Matsuoka J; Symmans WF; Tokes AM; Kulka J; Swanton C; Pusztai L
Breast Cancer Res Treat; 2013 Apr; 138(3):691-8. PubMed ID: 23504136
[TBL] [Abstract][Full Text] [Related]
18. Prediction of epigenetically regulated genes in breast cancer cell lines.
Loss LA; Sadanandam A; Durinck S; Nautiyal S; Flaucher D; Carlton VE; Moorhead M; Lu Y; Gray JW; Faham M; Spellman P; Parvin B
BMC Bioinformatics; 2010 Jun; 11():305. PubMed ID: 20525369
[TBL] [Abstract][Full Text] [Related]
19. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
[TBL] [Abstract][Full Text] [Related]
20. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.
Schneider J; Gonzalez-Roces S; Pollán M; Lucas R; Tejerina A; Martin M; Alba A
Breast Cancer Res; 2001; 3(3):183-91. PubMed ID: 11305953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
